Published • loading... • Updated
Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
The studies found olezarsen cut pancreatitis risk by 81% and evolocumab lowered heart attack risk by 35% in high-risk diabetes patients.
- Researchers presented new data at the American Diabetes Association's 2026 Scientific Sessions in New Orleans from June 5-8, demonstrating that Olezarsen and Evolocumab address common diabetes complications.
- Lead author Yu Mi Kang, MD, PhD, MPH, reported that Olezarsen lowered triglyceride levels and reduced acute pancreatitis risk by 81% in patients with diabetes.
- Clinical data from 1,063 patients showed that 50mg and 80mg doses of Olezarsen reduced excess blood fat by 64.8% in those with a diabetes history.
- Professor Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACC, of the University of Toronto, reported Evolocumab lowered "bad" cholesterol by more than 50% and reduced heart attack risk by 35%.
- Over 155 million Americans live with diabetes or prediabetes, facing elevated risks for cardiovascular disease and acute pancreatitis, making these medications' benefits significant for public health.
Insights by Ground AI
29 Articles
29 Articles
WJFW NewsWatch 12+28 Reposted by 28 other sources
Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
Once-Monthly Injection Reduced Triglycerides and the Risk of Acute Pancreatitis; Bi-Weekly Injection Lowered "Bad" Cholesterol and Cardiovascular Events
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources29
Leaning Left1Leaning Right4Center17Last UpdatedBias Distribution77% Center
Bias Distribution
- 77% of the sources are Center
77% Center
C 77%
R 18%
Factuality
To view factuality data please Upgrade to Premium
